BRCA1 and ovarian carcinoma: T1720A was the subject of several analyses including structural [70], [71], transcription [11], transactivation [71] and phospho-peptide binding assays [70] because it was the sole BRCA1 alteration in individuals considered to be at high risk for breast or ovarian cancer.